April 2016

Rheonix to Pursue Rapid Zika Virus Diagnostic

ITHACA, N.Y. — Rheonix, Inc., a developer of fully automated molecular testing solutions, in collaboration with New York University College of Dentistry (NYUCD), has received funding to develop a rapid diagnostic for Zika virus infection. The $656,414 award is an administrative supplement to an existing Small Business Innovation Research (SBIR) Phase I/II Fast-track grant from the National Institute of Dental and Craniofacial Research (NIDCR) of the National Institutes of Health… Read More »
Rheonix receives FDA Emergency Use Authorization for Automated COVID-19 Test.
Learn More